Month: March 2022

Digitally integrating Cone Beam Computed Tomography (CBCT) scan and intraoral scan data into ClinCheck treatment plans enables doctors to confidently expand diagnosis and treat a broader range of cases with Invisalign clear aligners TEMPE, Ariz., March 18, 2022 (GLOBE NEWSWIRE) — Align Technology, Inc. (“Align”) (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign system of clear aligners, iTero intraoral scanners, and exocad CAD/CAM software for digital orthodontics and restorative dentistry today announced the new Cone Beam Computed Tomography (CBCT) integration feature for ClinCheck digital treatment planning software, a user-friendly tool that combines roots, bone, and crowns into a single three-dimensional model that enables doctors to visualize a patient’s roots as part...

Santiago, Chile, March 18, 2022 (GLOBE NEWSWIRE) — Speaking at the launch of the Latin America Blockchain Accelerator (LABS) in Santiago, Chile, the CEO of HUMBL, Inc. (OTCQB:HMBL), Brian Foote, announced that it has launched “Project: Search 3.” The initiative will result in the production of “Search 3,” one of the world’s first modular, blockchain-based Web 3 search engines. The company announced that it is already well underway on the building of the technology, which is expected to ship to the global markets sometime in the first half of calendar year 2022. “The challenge of building a decentralized Web 3 that is still easily discoverable, well organized and verifiable on blockchain for users, is both groundbreaking and exciting,” said HUMBL CEO, Brian Foote. “We view Search 3 as a simple discovery layer that provides verifiable...

David Jemmett shares insights, counsel to help organizations globally to protect themselves from digital cybersecurity disaster SCOTTSDALE, Ariz., March 18, 2022 (GLOBE NEWSWIRE) — via InvestorWire — The Russian aggression in Ukraine is unlike any global conflict most people have seen in their lifetimes, creating both humanitarian crises as well as fomenting cybersecurity insurrection that few organizations are prepared to weather, said David Jemmett, CEO, Cerberus Cyber Sentinel Corporation (Nasdaq: CISO), a global Managed Compliance and Cybersecurity Provider (MCCP) based in Scottsdale, Ariz. CISA (Cybersecurity and Infrastructure Security Agency), the U.S. federal government’s key cybersecurity communications arm, recommended in a recent “Shields Up” posting that, due to the ongoing conflict in Ukraine, “all...

CHARLOTTE, N.C., March 18, 2022 (GLOBE NEWSWIRE) — DENTSPLY SIRONA Inc. (“Dentsply Sirona”) (Nasdaq: XRAY) today announced that the Company will participate in the Piper Sandler Virtual Dental Day. Don Casey, Chief Executive Officer, is scheduled to participate in a fireside chat discussion on Tuesday, March 29, 2022 at 1:00 pm ET. A live webcast will be available on the Investors section of the Dentsply Sirona website at https://investor.dentsplysirona.com. A replay of the webcast will be available for 30 days following the discussion. About Dentsply Sirona Dentsply Sirona is the world’s largest manufacturer of professional dental products and technologies, with a 135-year history of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions...

– 5th Annual Neuroscience Innovation Forum – – BIO-Europe Spring® 2022 – CUPERTINO, Calif., March 18, 2022 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in the following conferences in March and invites investors to participate in virtual one-on-one meetings. Please see additional details below:5th Annual Neuroscience Innovation Forum (NIF) – Registration Link  Panel: Advances in Neuropsychiatry Panel  Wednesday, March 23rd at 9:00am ET  Corporate...

TUCSON, Ariz., March 18, 2022 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that it has entered into a definitive securities purchase agreement to sell securities in a private placement with a leading healthcare investor. The gross proceeds to HTG from the private placement, before deducting the placement agent fees and other estimated fees and expenses related to the private placement, are expected to be approximately $7.5 million. HTG intends to use the net proceeds from the private placement for working capital and general corporate purposes.    Pursuant to the terms of the securities purchase agreement, HTG will issue 3,244,987 units at a price of $2.312 per unit to the investor (less $0.001 for each pre-funded...

SYDNEY, AUSTRALIA, March 18, 2022 (GLOBE NEWSWIRE) —  Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”) is pleased to announce new biomarker and multivariate analysis data from its Phase IIb AIPAC trial at ESMO’s Breast Cancer Congress 2022, which will take place onsite in Berlin, Germany and virtually on 3-5 May 2022. Immutep’s AIPAC trial evaluated its lead product candidate eftilagimod alpha (“efti”) in combination with paclitaxel chemotherapy in 227 patients with HER2-negative/HR positive metastatic breast cancer (HR+ MBC). Final Overall Survival results were reported in November 2021. The Company will announce the new biomarker and multivariate analysis data to the market and make the poster available on its website. The European Society for Medical Oncology (ESMO) is the the leading professional...

SYDNEY, AUSTRALIA, March 18, 2022 (GLOBE NEWSWIRE) —  Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), is pleased to announce the grant of patent no. 7030750 entitled “Antibody molecules to LAG-3 and uses thereof” by the Japanese Patent Office. This new Japanese patent was filed as a divisional application and follows the grant of the parent Japanese patent announced in 2019. Corresponding patents in this family have been granted in other territories including Australia, China, Europe and the United States, as announced in 2018 through 2021. The claims of the patent are directed to pharmaceutical compositions for use in the treatment of cancer, where the composition comprises LAG525 in a specific dose and for use in a defined treatment regimen. The compositions may also be administered in combination...

Key findings from evaluation of 59 Heme Samples and 10 Controls:OGM detected 162/164 SVs detected by standard cytogenetics methods of karyotyping and FISH OGM detected chromosomal aberrations missed by karyotyping and FISH in 35 cases OGM Sensitivity: 98.7% OGM Specificity: 100% Positive Predictive Value: 100% Negative Predictive Value: 98% OGM Accuracy: 99.2% First-Pass Success Rate: 100% Limit of Detection (LOD) for aneuploidies, translocations, interstitial deletions and duplications at 400X: 5% variant allele fractionSAN DIEGO, March 18, 2022 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (Nasdaq: BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™, the leading software solution for visualization, interpretation and reporting of genomic data, today announced the publication...

EVLI BANK PLC STOCK EXCHANGE RELEASE 18 MARCH 2022 AT 2.00 PM (EET/EEST) NOT FOR PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, SOUTH AFRICA, HONG KONG, JAPAN, CANADA OR SINGAPORE, NEW ZEALAND, THE UNITED STATES OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION OR DISTRIBUTION WOULD VIOLATE APPLICABLE LAWS OR RULES OR WOULD REQUIRE ADDITIONAL DOCUMENTS TO BE COMPLETED OR REGISTERED OR REQUIRE ANY MEASURE TO BE UNDERTAKEN IN ADDITION TO THE REQUIREMENTS UNDER FINNISH LAW. SEE “IMPORTANT NOTICE” BELOW.THE FINNISH FINANCIAL SUPERVISORY AUTHORITY HAS APPROVED A SUPPLEMENT TO THE FINNISH LANGUAGE MERGER PROSPECTUS PREPARED FOR THE MERGER OF THE REMAINING EVLI AND FELLOW FINANCE PLC The Finnish Financial Supervisory Authority has today on 18 March 2022, approved a supplement to the Finnish language...